Login to Your Account

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

By Nuala Moran

Wednesday, September 25, 2002
LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription